...
首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >Rapid identification of urokinase plasminogen activator inhibitors from Traditional Chinese Medicines based on ultrafiltration, LC-MS and in silico docking
【24h】

Rapid identification of urokinase plasminogen activator inhibitors from Traditional Chinese Medicines based on ultrafiltration, LC-MS and in silico docking

机译:基于超滤,LC-MS和Silico对接的中药尿激酶纤溶酶原激活剂抑制剂的快速鉴定

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The urokinase plasminogen activator (uPA) is regarded as the crucial trigger for plasmin generation, which is involved in several diseases especially for neoplasm metastasis. In this study, an efficient approach integrating ultrafiltration, LC/MS, bioassay and in silico docking, was proposed for rapidly detecting uPA ligands from Traditional Chinese Medicines (TCMs). Forty-two TCM5 were initially assessed, and as illustrative case studies, Galla Chinensis and Sanguisorbae Radix, which appeared significant inhibitory activities on uPA, were chosen to develpe and verify the strategy. A total of seven uPA ligands were successfully detected and identified. Two of them, pentagalloylglucose and 28-O-beta-D-glucopyranosyl pomolic acid, were demonstrated to be potential inhibitors, with IC50 at 1.639 mu M and 37.82 mu M repectively. Furthermore, a combinatorial compound library screening combined with in silico docking assay, was revealed that ursolic acid (IC50 = 2.623 mu M) was also speculated to be a potent parent structure for inhibition of uPA. This approach offers a multidimensional perspective to discover uPA-binding leading compounds from TCMs or other complex mixtures, which would provide an efficient route for drug discovery. (C) 2018 Elsevier B.V. All rights reserved.
机译:尿激酶纤溶酶原激活剂(UPA)被认为是纤溶酶产生的关键触发,其涉及尤其是肿瘤转移的几种疾病。在该研究中,提出了一种有效的方法,用于快速检测来自中药(TCMS)的UPA配体的高温滤网,LC / MS,生物测划艇和硅基粘接方法。最初评估了四十二届TCM5,作为说明性案例研究,Galla Chinensis和Sanguisorbae addix似乎对UPA的显着抑制活性进行了选择,并验证了策略。总共检测到七种UPA配体并确定。它们中的两种,戊烯酰基葡萄糖和28-O-β-D-吡喃葡萄糖囊基极酸被证明是潜在的抑制剂,IC50在1.639亩和37.82μm米处重叠。此外,将组合化合物文库筛选与硅基对接测定相结合,筛选熊酸(IC50 =2.623μm),也推测是抑制UPA的有效母体结构。该方法提供了多维视角,以发现来自TCMS或其他复杂混合物的UPA结合的前导化合物,这将为药物发现提供有效的途径。 (c)2018年elestvier b.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号